Price to Sales (P/S)
since 2005
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Dividend Discount Model (DDM)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Amgen Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Product sales1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Amgen Inc. Annual Report.
The analysis of the financial data over the presented periods reveals several notable trends regarding share price, sales per share, and the price-to-sales (P/S) ratio.
- Share Price
- The share price shows a fluctuating pattern with an initial decline from $73.49 in 2006 to a low of $45.53 in 2008. Following this trough, a general upward trend is apparent, accelerating notably from 2012 onward. The share price reaches a peak of $291.16 in 2025, representing a substantial increase over the entire period. Despite minor fluctuations, the overall trajectory is markedly positive, indicating improved market valuation.
- Sales per Share
- Sales per share exhibit consistent growth throughout the time frame. Starting at $10.15 in 2006, sales increase steadily each year, reaching $59.62 by 2025. This upward trend suggests strong operational performance and expanding revenue generation on a per-share basis, underscoring business growth and increased profitability potential.
- Price-to-Sales (P/S) Ratio
- The P/S ratio experiences a decline from 7.24 in 2006 to a low around 3.32 in 2011, indicating that the share price fell relative to sales or sales grew faster than the share price during this period. Post-2011, the ratio generally trends upward, fluctuating between approximately 3.5 and 6.13 through subsequent years. There is an observed peak in 2015, after which the ratio settles around the mid-5 range till 2025 with some variability. This pattern implies that market valuation relative to sales became more favorable after 2011 but with moderate oscillations, reflecting changing investor sentiment or market conditions.
In summary, the data demonstrate a strong recovery and growth in share price following the 2008 downturn, accompanied by steady increases in sales per share. The P/S ratio's initial decline followed by stabilization and moderate growth indicates evolving market valuation dynamics, balancing sales growth with share price performance.
Comparison to Competitors
Amgen Inc., P/S, long-term trends, comparison to competitors
| Amgen Inc. | AbbVie Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 | ||||||||||||
| Feb 14, 2024 | ||||||||||||
| Feb 9, 2023 | ||||||||||||
| Feb 16, 2022 | ||||||||||||
| Feb 9, 2021 | ||||||||||||
| Feb 12, 2020 | ||||||||||||
| Feb 13, 2019 | ||||||||||||
| Feb 13, 2018 | ||||||||||||
| Feb 14, 2017 | ||||||||||||
| Feb 16, 2016 | ||||||||||||
| Feb 19, 2015 | ||||||||||||
| Feb 24, 2014 | ||||||||||||
| Feb 27, 2013 | ||||||||||||
| Feb 29, 2012 | ||||||||||||
| Feb 25, 2011 | ||||||||||||
| Mar 1, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 28, 2008 | ||||||||||||
| Feb 28, 2007 | ||||||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Amgen Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Amgen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Amgen Inc., P/S, long-term trends, comparison to industry (health care)
| Amgen Inc. | Health Care | |
|---|---|---|
| Feb 14, 2025 | ||
| Feb 14, 2024 | ||
| Feb 9, 2023 | ||
| Feb 16, 2022 | ||
| Feb 9, 2021 | ||
| Feb 12, 2020 | ||
| Feb 13, 2019 | ||
| Feb 13, 2018 | ||
| Feb 14, 2017 | ||
| Feb 16, 2016 | ||
| Feb 19, 2015 | ||
| Feb 24, 2014 | ||
| Feb 27, 2013 | ||
| Feb 29, 2012 | ||
| Feb 25, 2011 | ||
| Mar 1, 2010 | ||
| Feb 27, 2009 | ||
| Feb 28, 2008 | ||
| Feb 28, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).